Erratum
for
Saltz et al., J Clin Oncol 25 (30) 4793-4799.
Journal of Clinical Oncology, Vol 26, No 3 (January 20), 2008: pp. 514
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.2611
ERRATUM
The October 20, 2007, article by Saltz et al entitled, "Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy" (J Clin Oncol 25:4793-4799, 2007) contained errors.
In Figure 1, the response data were mislabeled. The corrected figure is reprinted below in its entirety.
View larger version (14K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
|
Fig 1. Maximum percent change in target lesion size by patient during sunitinib treatment (n = 72; 10 patients withdrew from the study before their first restaging scan). One patient with SD has a maximal change of zero, and is not visible in this graph. PR, partial response; SD, stable disease; RECIST, Response Evaluation Criteria in Solid Tumors Group.
|
|
In Figure 2A, the median time to tumor progression for the prior bevacizumab cohort was given as 2.5 months, whereas it should have been 2.2 months.
The online version has been corrected in departure from the print.
|
